Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ROS1 Fusions in Cancer: A Review
Arnaud Uguen, Marc De Braekeleer
Future Oncology (2016) Vol. 12, Iss. 16, pp. 1911-1928
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du, Christine M. Lovly
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 866
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 14, pp. 1405-1411
Open Access | Times Cited: 293
Patterns and mechanisms of structural variations in human cancer
Kijong Yi, Young Seok Ju
Experimental & Molecular Medicine (2018) Vol. 50, Iss. 8, pp. 1-11
Open Access | Times Cited: 99
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, et al.
Cancer Treatment Reviews (2021) Vol. 96, pp. 102179-102179
Open Access | Times Cited: 89
Tyrosine Kinase Receptors in Oncology
Jorge Esteban-Villarrubia, J.J. Soto Castillo, Javier Pozas, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8529-8529
Open Access | Times Cited: 78
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Alberto D’Angelo, Navid Sobhani, Robert Chapman, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3293-3293
Open Access | Times Cited: 77
The oncogenic fusion landscape in pediatric CNS neoplasms
Mieke Roosen, Zelda Odé, Jens Bunt, et al.
Acta Neuropathologica (2022) Vol. 143, Iss. 4, pp. 427-451
Open Access | Times Cited: 34
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions
Hiroki Sato, Adam J. Schoenfeld, Evan Siau, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 12, pp. 2932-2945
Open Access | Times Cited: 42
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Angela Rina, Debora Maffeo, Francesca Minnai, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2882-2882
Open Access | Times Cited: 5
Fluorescence in situ hybridization in surgical pathology: principles and applications
Liang Cheng, Shaobo Zhang, Lisha Wang, et al.
The Journal of Pathology Clinical Research (2017) Vol. 3, Iss. 2, pp. 73-99
Open Access | Times Cited: 41
Kinase Fusions in Spitz Melanocytic Tumors: The Past, the Present, and the Future
Maged Daruish, Francesca Ambrogio, Anna Colagrande, et al.
Dermatopathology (2024) Vol. 11, Iss. 1, pp. 112-123
Open Access | Times Cited: 4
Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
Frédéric Dugay, Francisco Llamas‐Gutierrez, Marjory Gournay, et al.
Oncotarget (2017) Vol. 8, Iss. 32, pp. 53336-53351
Open Access | Times Cited: 38
Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
Yueming He, Sheng Wang, Weiguo Hu, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2019) Vol. 27, Iss. 8, pp. 901-910
Open Access | Times Cited: 30
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma
Chunxiao Liu, Zhengyu Zha, Chenhao Zhou, et al.
Journal of Hepatology (2020) Vol. 74, Iss. 4, pp. 907-918
Open Access | Times Cited: 28
Exploring the Profiles of ROS1 Tyrosine Kinase: A Structural Analysis of G2032R and D2033N Mutations
Syed Ikramul Hasan
International Journal of Applied and Basic Medical Research (2025) Vol. 15, Iss. 1, pp. 4-10
Closed Access
Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study
Alper Topal, Goncagül Akdağ, Sedat Yıldırım, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 490-490
Open Access
Oncogenic gene fusions in cancer: from biology to therapy
Stephen V. Liu, Misako Nagasaka, Judith Atz, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer
Barbara Melosky, Normand Blais, Parneet Cheema, et al.
Current Oncology (2018) Vol. 25, Iss. 1, pp. 73-82
Open Access | Times Cited: 29
ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer
Dilara Akhoundova, Saskia Hussung, Smruthy Sivakumar, et al.
International Journal of Cancer (2022) Vol. 151, Iss. 12, pp. 2161-2171
Open Access | Times Cited: 15
Physiologically driven nanodrug delivery system for targeted lung cancer treatment
S Zhang, Xia Li, Yang Liu, et al.
Exploration of Medicine (2024), pp. 280-311
Open Access | Times Cited: 3
Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study
Cecily P. Vaughn, José Luís Costa, Harriet Feilotter, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 25
Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas
Quentin Bayard, Stefano Caruso, Gabrielle Couchy, et al.
Gut (2020) Vol. 69, Iss. 9, pp. 1667-1676
Closed Access | Times Cited: 23
Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma
Yoshiko Nakano, Arata Tomiyama, Takashi Kohno, et al.
Brain Tumor Pathology (2018) Vol. 36, Iss. 1, pp. 14-19
Closed Access | Times Cited: 22
GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors
Timothy E. Richardson, Karen Tang, Varshini Vasudevaraja, et al.
Journal of Neuropathology & Experimental Neurology (2019) Vol. 78, Iss. 12, pp. 1089-1099
Open Access | Times Cited: 22
Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
Liang Zeng, Yizhi Li, Lili Xiao, et al.
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 6937-6945
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top